Basophil Activation Test to Optimize the Diagnosis of Adverse Effects Following Immunization to Vaccines
Abstract
Adverse effects following immunization to vaccines (AEFI) are considered extremely rare events, the occurrence of which could gain a major role in optimizing allergy diagnosis by cellular tests. The urgent need to eradicate infectious diseases from population, is the main goal of vaccination campaign, therefore its successful outcome should be almost undisputable. Basophil Activation Test (BAT) is commonly used to ascertain a type I hypersensitivity reaction, often replacing reasability tests. Therefore, flow cytometry assay of basophil, as performed in BATs, is employed to test if a particular antigen elicits some activatory response from cells. The allergic subject may undergo an AEFI to vaccine not necessarily by an atopic reaction with an allergen within vaccines but because of the existence of an asymptomatic or not diagnosed inflammatory chronic allergy or other immune-disregulating allergy disorder in the subject. BAT, also in its basilar fashion, might be used from a simple heparinized whole blood specimen, but its application in diagnosing allergy before mandatory of facultative vaccination, must be associated to improve other diagnostic tools, at least in its pivotal application. If the application of BAT can be suggested to improve allergy diagnosis by introducing a cellular test in routinely used tools, such as sIgE and SPT, its use, due to possible expertise-consuming and relatively expensive issues, can be included in a specialized allergy consultancy panel as an exploratory approach of allergy inflammation, for which a subject undergoing immunization by vaccines is suggested to undergo and advised to sign an informed consent for BAT performing. This may extend BAT use in many other forms of chronic allergy and immunity disorders related to AEFI with vaccines.
1. Demicheli V, Rivetti A, Debalini MG, Di Pietrantonj C.Vaccines for measles, mumps and rubella in children. Cochrane Database Syst Rev 2012; 2:CD004407.
2. Bar-On ES, Goldberg E, Hellmann S, Leibovici L.Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primaryprevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB). Cochrane Database Syst Rev 2012; 4:CD005530.
3. Zimmerman RK, Wolfe RM, Fox DE, Fox JR, Nowalk MP, Troy JA, et al. Vaccine criticism on the World Wide Web. J Med Internet Res 2005; 7(2):e17
4. Opel DJ, Diekema DS, Marcuse EK. A critique of criteria for evaluating vaccines for inclusion in mandatory school immunization programs. Pediatrics 2008; 122(2):e504-10.
5. Horn L, Howard C, Waller J, Ferris DG. Opinions of parents about school-entry mandates for the human papillomavirus vaccine. J Low Genit Tract Dis 2010;14(1):43-8.
6. Ferro A, Cinquetti S, Menegon T, Napoletano G, Bertoncello L, Valsecchi M. (Overcoming mandatory vaccination policy: first steps). Ann Ig 2008; 20(3 Suppl 1):3-8.
7. Poscia A, Santoro A, Collamati A, de Belvis AG, Ricciardi W, Moscato U. (Availability and quality of vaccines information on the Web: a systematic review and implication in Public Health). Ann Ig 2012;24(2):113-21.
8. Pozza F, Piovesan C, Russo F, Bella A, Pezzotti P, Emberti Gialloreti L. Impact of universal vaccination on the epidemiology of varicella in Veneto, Italy. Vaccine 2011; 29(51):9480-7.
9. Muscat M, Zimmerman L, Bacci S, Bang H, Glismann S, Mølbak K, et al. Toward rubella elimination in Europe: an epidemiological assessment. Vaccine 2012;30(11):1999-2007.
10. Zanoni G, Berra P, Lucchi I, Ferro A, O'Flanagan D, Levy-Bruhl D, et al. Vaccine adverse event monitoring systems across the European Union countries: time for unifying efforts. Vaccine 2009; 27(25-26):3376-84.
11. Salisbury DM. Should childhood vaccination bemandatory? No. BMJ 2012; 344:e2435.
12. van Klooster TM, Kemmeren JM, van der Maas NA, de Melker HE. Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands. Vaccine 2011;29(28):4601-7.
13. van der Maas NA, Kemmeren JM, de Melker HE. (Safety of the bivalent human papillomavirus vaccine--results following administration of more than 192,000 doses). Ned Tijdschr Geneeskd 2009; 153:A964.
14. Klein NP, Lewis E, Baxter R, Weintraub E, Glanz J, Naleway A, et al. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics 2012;129(5):809-14.
15. Langley JM, Scheifele DW, Quach C, Vanderkooi OG, Ward B, McNeil S, et al. Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study. Vaccine 2012; 30(23):3389-94.
16. Coombes R. Vaccine disputes. BMJ 2009; 338:b2435.
17. Schwartz JL, Caplan AL. Ethics of vaccination programs.Curr Opin Virol 2011; 1(4):263-7.
18. Segura Benedicto A. [The putative link between the MMR vaccine and autism and refusal to vaccinate]. Gac Sanit 2012; 26(4):366-71.
19. Parry HM, Damery S, Fergusson A, Draper H, Bion J, Low AE. Pandemic influenza A (H1N1) 2009 in a critical care and theatre setting: beliefs and attitudes towards staff vaccination. J Hosp Infect. 2011; 78(4):302-7.
20. National Center for Immunization and Respiratory Diseases, CDC; Centers for Disease Control and Prevention (CDC). Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009; 58(RR-10):1-8.
21. Vellozzi C, Broder KR, Haber P, Guh A, Nguyen M, Cano M, et al. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010. Vaccine 2010;28(45):7248-55.
22. Coop CA, Balanon SK, White KM, Whisman BA, Rathkopf MM. Anaphylaxis from the influenza virus vaccine. Int Arch Allergy Immunol 2008; 146(1):85-8.
23. Fung I, Spergel JM. Administration of influenza vaccine to pediatric patients with egg-induced anaphylaxis. J Allergy Clin Immunol 2012; 129(4):1157-9.
24. Hawkes CP, Mulcair S, Hourihane JO. Is hospital based MMR vaccination for children with egg allergy here to stay? Ir Med J 2010; 103(1):17-9.
25. Chung EY, Huang L, Schneider L. Safety of influenza vaccine administration in egg-allergic patients. Pediatrics 2010; 125(5):e1024-30.
26. Centers for Disease Control and Prevention (CDC).Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60(33):1128.
27. Zanoni G, Ferro A, Valsecchi M, Tridente G. The "Green Channel" of the Veneto region as a model for vaccine safety monitoring in Italy. Vaccine 2005; 23(17-18):2354-8.
28. de Weck AL, Sanz ML, Gamboa PM, Aberer W, Bienvenu J, Blanca M, et al. Diagnostic tests based on human basophils: more potentials and perspectives than pitfalls. Int Arch Allergy Immunol 2008; 146(3):177-89.
29. Chirumbolo S. Basophil Activation Test in Allergy: Time for an Update? Int Arch Allergy Immunol 2012;158(2):99-114.
30. Yavuz ST, Sahiner UM, Sekerel BE, Tuncer A, Kalayci O, Sackesen C. Anaphylactic reactions to measles- mumps-rubella vaccine in three children with allergies to hen's egg and cow's milk. Acta Paediatr 2011;100(8):e94-6.
31. Kattan JD, Konstantinou GN, Cox AL, Nowak-Węgrzyn A, Gimenez G, Sampson HA, et al. Anaphylaxis to diphtheria, tetanus, and pertussis vaccines among children with cow's milk allergy. J Allergy Clin Immunol 2011;128(1):215-8.
32. McDonald KL, Huq SI, Lix LM, Becker AB, Kozyrskyj AL. Delay in diphtheria, pertussis, tetanus vaccination is associated with a reduced risk of childhood asthma. J Allergy Clin Immunol 2008; 121(3):626-31.
33. Boulet LP. Asymptomatic airway hyperresponsiveness: acuriosity or an opportunity to prevent asthma? Am J Respir Crit Care Med 2003; 167(3):371-8.
34. Bousquet J, Anto JM, Bachert C, Bousquet PJ, Colombo P, Crameri R, et al. Factors responsible for differences between asymptomatic subjects and patients presenting an IgE sensitization to allergens. A GA2LEN project. Allergy 2006; 61(6):671-80.
35. Pala G, Pignatti P, Perfetti L, Caminati M, Gentile E, Moscato G. Usefulness of basophil activation test in diagnosis of occupational nonasthmatic eosinophilic bronchitis. Allergy 2010; 65(7):927-9.
36. Thaminy A, Lamblin C, Perez T, Bergoin C, Tonnel AB, Wallaert B. Increased frequency of asymptomatic bronchial hyperresponsiveness in nonasthmatic patients with food allergy. Eur Respir J 2000; 16(6):1091-4.
37. Gaglani MJ. Rationale and approach to target children with asthma for annual influenza immunization. Semin Pediatr Infect Dis 2002; 13(2):97-103.
38. Friedman BC, Goldman RD. Influenza vaccination for children with asthma. Can Fam Physician 2010;56(11):1137-9.
39. Braga M, Quecchia C, Cavallucci E, Di Giampaolo L, Schiavone C, Petrarca C, et al. T regulatory cells in allergy. Int J Immunopathol Pharmacol 2011; 24(1Suppl):55S-64S.
40. Warde N. Lupus nephritis: Activated basophils exacerbate lupus nephritis by amplifying production of autoreactive IgE. Nat Rev Rheumatol 2010; 6(8):438.
41. Lehmann HC, Hartung HP, Kieseier BC, Hughes RA.Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis 2010; 10(9):643-51.
42. Charles N, Rivera J. Basophils and autoreactive IgE in the pathogenesis of systemic lupus erythematosus. Curr Allergy Asthma Rep 2011; 11(5):378-87.
43. Kawakami T. Basophils now enhance memory. Nat Immunol 2008; 9(7):720-1.
44. Roan F, Bell BD, Stoklasek TA, Kitajima M, Han H, Ziegler SF. The multiple facets of thymic stromal lymphopoietin (TSLP) during allergic inflammation and beyond. J Leukoc Biol 2012; 91(6):877-86.
45. Feyerabend TB, Weiser A, Tietz A, Stassen M, Harris N,Kopf M, et al. Cre-mediated cell ablation contests mast cell contribution in models of antibody- and T cell- mediated autoimmunity. Immunity 2011; 35(5):832-44.
46. Leventhal JS, Berger EM, Brauer JA, Cohen DE.Hypersensitivity reactions to vaccine constituents: a case series and review of the literature. Dermatitis 2012;23(3):102-9.
47. Chirumbolo S. Monitoring of CD63% in basophil activation test and suggested new parameters for allergy diagnosis. Inflamm Res 2012; 61(2):171-6.
| Files | ||
| Issue | Vol 12, No 3 (2013) | |
| Section | Articles | |
| Keywords | ||
| Adverse effects to vaccines Allergy Basophil Basophil activation test Flow cytometry | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
